Seelos Therapeutics Inc. [NASDAQ: SEEL] plunged by -$1.26 during the normal trading session on Monday and reaching a high of $5.24 during the day while it closed the day at $3.93. The company report on May 17, 2021 that Seelos Therapeutics Announces Positive Topline Data from the Open-Label Study of SLS-002 (Intranasal Racemic Ketamine), Demonstrating a Significant Treatment Effect and a Well Tolerated Safety Profile for Acute Suicidal Ideation and Behavior in Patients with Major Depressive Disorder.
– SLS-002 Demonstrated a 76.5% Response Rate in the Primary Endpoint on MADRS 24 Hours After First Dose, with a Mean Reduction in Total Score from 39.4 to 14.5 points.
3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
– A 92.9% Response Rate was Observed in a Key Secondary Endpoint on Day 16 (after five doses), Achieving a Mean MADRS Score of 7.4 points.
Seelos Therapeutics Inc. stock has also loss -18.97% of its value over the past 7 days. However, SEEL stock has declined by -1.50% in the 3 months of the year. Over the past six months meanwhile, it has gained 328.10% and gained 148.73% year-on date.
The market cap for SEEL stock reached $274.94 million, with 69.05 million shares outstanding and 66.92 million shares in the current float. Compared to the average trading volume of 9.58M shares, SEEL reached a trading volume of 19923391 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Seelos Therapeutics Inc. [SEEL]:
ROTH Capital have made an estimate for Seelos Therapeutics Inc. shares, keeping their opinion on the stock as Neutral, with their previous recommendation back on May 17, 2021. While these analysts kept the previous recommendation, B. Riley Securities raised their target price to Buy. The new note on the price target was released on March 30, 2021, representing the official price target for Seelos Therapeutics Inc. stock. Previously, the target price had yet another raise to $4, while The Benchmark Company analysts kept a Speculative Buy rating on SEEL stock.
The Average True Range (ATR) for Seelos Therapeutics Inc. is set at 0.56 The Price to Book ratio for the last quarter was 10.92, with the Price to Cash per share for the same quarter was set at 0.55.
SEEL stock trade performance evaluation
Seelos Therapeutics Inc. [SEEL] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -18.97. With this latest performance, SEEL shares dropped by -25.29% in over the last four-week period, additionally plugging by 328.10% over the last 6 months – not to mention a rise of 305.15% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for SEEL stock in for the last two-week period is set at 35.60, with the RSI for the last a single of trading hit 29.46, and the three-weeks RSI is set at 40.73 for Seelos Therapeutics Inc. [SEEL]. The present Moving Average for the last 50 days of trading for this stock 4.92, while it was recorded at 4.70 for the last single week of trading, and 2.31 for the last 200 days.
Seelos Therapeutics Inc. [SEEL]: An insightful look at the core fundamentals
Return on Total Capital for SEEL is now -305.30, given the latest momentum, and Return on Invested Capital for the company is -387.52. Return on Equity for this stock declined to -1,489.36, with Return on Assets sitting at -133.62. When it comes to the capital structure of this company, Seelos Therapeutics Inc. [SEEL] has a Total Debt to Total Equity ratio set at 378.07. Additionally, SEEL Total Debt to Total Capital is recorded at 79.08, with Total Debt to Total Assets ending up at 55.58. Long-Term Debt to Equity for the company is recorded at 283.55, with the Long-Term Debt to Total Capital now at 59.31.
Reflecting on the efficiency of the workforce at the company, Seelos Therapeutics Inc. [SEEL] managed to generate an average of -$1,910,100 per employee.Seelos Therapeutics Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 3.10 and a Current Ratio set at 3.10.
Earnings per share (EPS) analysis for Seelos Therapeutics Inc. [SEEL] stock
With the latest financial reports released by the company, Seelos Therapeutics Inc. posted -0.08/share EPS, while the average EPS was predicted by analysts to be reported at -0.13/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 38.50%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for SEEL.
Seelos Therapeutics Inc. [SEEL]: Insider Ownership positions
There are presently around $97 million, or 14.70% of SEEL stock, in the hands of institutional investors. The top three institutional holders of SEEL stocks are: INVESCO LTD. with ownership of 3,464,259, which is approximately New of the company’s market cap and around 6.55% of the total institutional ownership; VANGUARD GROUP INC, holding 2,921,164 shares of the stock with an approximate value of $11.48 million in SEEL stocks shares; and MANGROVE PARTNERS, currently with $8.5 million in SEEL stock with ownership of nearly New of the company’s market capitalization.
Positions in Seelos Therapeutics Inc. stocks held by institutional investors increased at the end of May and at the time of the May reporting period, where 62 institutional holders increased their position in Seelos Therapeutics Inc. [NASDAQ:SEEL] by around 18,726,914 shares. Additionally, 11 investors decreased positions by around 1,394,444 shares, while 4 investors held positions by with 4,555,244 shares. The mentioned changes placed institutional holdings at 24,676,602 shares, according to the latest SEC report filing. SEEL stock had 49 new institutional investments in for a total of 16,685,825 shares, while 4 institutional investors sold positions of 758,960 shares during the same period.